Lexeo Therapeutics (LXEO) Common Equity (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Common Equity of $231.5 million for Q1 2026, down 6.15% sequentially from $246.7 million in Q4 2025, and up 162.72% YoY from $88.1 million in Q1 2025.
Lexeo Therapeutics (LXEO) Common Equity (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Common Equity for 5 years, with the latest figure at $231.5 million in Q1 2026.
- Quarterly Common Equity rose 162.72% year-over-year to $231.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $231.5 million (up 162.72% YoY) and the FY2025 annual result came in at $246.7 million, up 111.11% from the prior year.
- Common Equity slipped to $231.5 million in Q1 2026 per LXEO's latest filing, from $246.7 million in the prior quarter.
- Over five years, Common Equity peaked at $246.7 million in Q4 2025 and troughed at -$162.8 million in Q3 2023.
- A 5-year average of $59.6 million and a median of $116.8 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2023 and 2024: Common Equity sank 64.49% in 2023, then surged 239.46% in 2024.
- Over 5 years, Common Equity stood at -$113.0 million in 2022, then surged by 200.51% to $113.5 million in 2023, then increased by 2.91% to $116.8 million in 2024, then soared by 111.11% to $246.7 million in 2025, then slipped by 6.15% to $231.5 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $231.5 million, $246.7 million, and $120.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | 235.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 235.06 Mn |
| Mar 31, 2026 | 231.50 Mn |
| Dec 31, 2025 | 246.67 Mn |
| Sep 30, 2025 | 120.83 Mn |
| Jun 30, 2025 | 138.22 Mn |
| Mar 31, 2025 | 88.12 Mn |
| Dec 31, 2024 | 116.84 Mn |
| Sep 30, 2024 | 139.33 Mn |
| Jun 30, 2024 | 164.95 Mn |
| Mar 31, 2024 | 182.95 Mn |
| Dec 31, 2023 | 113.54 Mn |
| Sep 30, 2023 | -162.81 Mn |
| Jun 30, 2023 | -143.62 Mn |
| Mar 31, 2023 | -131.18 Mn |
| Dec 31, 2022 | -112.95 Mn |
| Sep 30, 2022 | -98.98 Mn |